1. Стукалова О.В. Магнитно-резонансная томография в диагностике ИБС. Российский электронный журнал лучевой диагностики. 2011;1(3):82-7 [Stukalova OV. MRI in diagnosis of ischemic heart disease. Russian Electronic Journal of Radiology. 2011;1(3):82-7 (In Russ.)].
2. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69. doi: 10.1093/eurheartj/ehy462
3. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol. 2009;55:1-16. doi: 10.1016/j.jacc.2009.06.059
4. Bulluck H, Dharmakumar R, Arai AE, et al. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. Circulation. 2018;137(18):1949-64. doi: 10.1161/CIRCULATIONAHA.117.030693
5. Bruder O, Wagner A, Lombardi M, et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry – multinational results from 57 centers in 15 countries. J Cardiovasc Magn Reson. 2013;15. doi: 10.1186/1532-429X-15-9
6. Vasquez M, Nagel E. Clinical indications for cardiovascular magnetic resonance. Heart. 2019;105:1755-62. doi: 10.1136/heartjnl-2018-312971
7. Shellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla. J Cardiovasc Magn Reson. 2005;7(2):415-9. doi: 10.1081/jcmr-200053588
8. Levine GN, Gomes AS, Arai AE, et al. American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Radiology and Intervention. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2007;116(24):2878-91. doi: 10.1161/CIRCULATIONAHA.107.187256
9. Porto I, Selvanayagam J, Ashar V, et al. Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation. Am J Cardiol. 2005;96(3):366-8. doi: 10.1016/j.amjcard.2005.03.077
10. Patel MR, Albert TS, Kandzari DE, et al. Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. Radiology. 2006;240(3):674-80. doi: 10.1148/radiol.2403050740
11. Глушко Л.А., Бокерия О.Л. Системы для электротерапии сердца, совместимые с магнитно-резонансной томографией. Анналы аритмологии. 2015;12(4):225-33 [Glushko O, Bockeria L. The devices for electrotherapy of the heart, compatible with magnetic resonance tomography. Annaly aritmologii. 2015;12:225-33 (In Russ.)]. 
doi: 10.15275/annaritmol.2015.4.4
12. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16(12):2619-21. doi: 10.1007/s00330-006-0495-8
13. Thomsen HS (Ed.) Contrast media. Safety issues and ESUR guidelines. Berlin: Heidelberg; New York: Springer, 2006.
14. Cowling T, Frey N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults Undergoing Magnetic Resonance Imaging: A Review of Safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.
15. Choi JW, Moon WJ. Gadolinium Deposition in the Brain: Current Updates. Korean J Radiol. 2019;20(1):134-47. doi: 10.3348/kjr.2018.0356
16. Zhang L, Gooya A, Pereanez M, et al. Automatic Assessment of Full Left Ventricular Coverage in Cardiac Cine Magnetic Resonance Imaging with Fisher Discriminative 3D CNN. IEEE Trans Biomed Eng. 2018;66(7):1975-86. doi: 10.1109/TBME.2018.2881952
17. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992-2002. doi: 10.1161/01.cir.100.19.1992
18. Breithardt G, Borggrefe M, Martinez-Rubio A, Budde T. Pathophysiological mechanisms of ventricular tachyarrhythmias. Eur Heart J. 1989;10(Suppl. E):9-18. doi: 10.1093/eurheartj/10.suppl_e.9
19. Castellanos A Jr, Lemberg L, Arcebal AG. Mechanisms of slow ventricular tachycardias in acute myocardial infarction. Dis Chest. 1969;56(6):470-6. doi: 10.1378/chest.56.6.470
20. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115(15):2006-14. doi: 10.1161/CIRCULATIONAHA.106.653568
21. Abbas A, Matthews GH, Brown IW, et al. Cardiac MR assessment of microvascular obstruction. Br J Radiol. 2015;88(1047):20140470. doi: 10.1259/bjr.20140470
22. Bulluck H, Rosmini S, Abdel-Gadir A, et al. Diagnostic performance of T1and T2mapping to detect intra myocardial hemorrhage in reperfused ST segment elevation myocardial infarction (STEMI) patients. J Magn Reson Imaging. 2017;46:877-86. doi: 10.1002/jmri.25638

________________________________________________

1. Stukalova OV. MRI in diagnosis of ischemic heart disease. Russian Electronic Journal of Radiology. 2011;1(3):82-7 (In Russ.)
2. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69. doi: 10.1093/eurheartj/ehy462
3. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol. 2009;55:1-16. doi: 10.1016/j.jacc.2009.06.059
4. Bulluck H, Dharmakumar R, Arai AE, et al. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. Circulation. 2018;137(18):1949-64. doi: 10.1161/CIRCULATIONAHA.117.030693
5. Bruder O, Wagner A, Lombardi M, et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry – multinational results from 57 centers in 15 countries. J Cardiovasc Magn Reson. 2013;15. doi: 10.1186/1532-429X-15-9
6. Vasquez M, Nagel E. Clinical indications for cardiovascular magnetic resonance. Heart. 2019;105:1755-62. doi: 10.1136/heartjnl-2018-312971
7. Shellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla. J Cardiovasc Magn Reson. 2005;7(2):415-9. doi: 10.1081/jcmr-200053588
8. Levine GN, Gomes AS, Arai AE, et al. American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Radiology and Intervention. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2007;116(24):2878-91. doi: 10.1161/CIRCULATIONAHA.107.187256
9. Porto I, Selvanayagam J, Ashar V, et al. Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation. Am J Cardiol. 2005;96(3):366-8. doi: 10.1016/j.amjcard.2005.03.077
10. Patel MR, Albert TS, Kandzari DE, et al. Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. Radiology. 2006;240(3):674-80. doi: 10.1148/radiol.2403050740
11. Glushko O, Bockeria L. The devices for electrotherapy of the heart, compatible with magnetic resonance tomography. Annaly aritmologii. 2015;12:225-33 (In Russ.) 
doi: 10.15275/annaritmol.2015.4.4
12. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16(12):2619-21. 
doi: 10.1007/s00330-006-0495-8
13. Thomsen HS (Ed.) Contrast media. Safety issues and ESUR guidelines. Berlin: Heidelberg; New York: Springer, 2006.
14. Cowling T, Frey N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults Undergoing Magnetic Resonance Imaging: A Review of Safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.
15. Choi JW, Moon WJ. Gadolinium Deposition in the Brain: Current Updates. Korean J Radiol. 2019;20(1):134-47. doi: 10.3348/kjr.2018.0356
16. Zhang L, Gooya A, Pereanez M, et al. Automatic Assessment of Full Left Ventricular Coverage in Cardiac Cine Magnetic Resonance Imaging with Fisher Discriminative 3D CNN. IEEE Trans Biomed Eng. 2018;66(7):1975-86. doi: 10.1109/TBME.2018.2881952
17. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992-2002. doi: 10.1161/01.cir.100.19.1992
18. Breithardt G, Borggrefe M, Martinez-Rubio A, Budde T. Pathophysiological mechanisms of ventricular tachyarrhythmias. Eur Heart J. 1989;10(Suppl. E):9-18. doi: 10.1093/eurheartj/10.suppl_e.9
19. Castellanos A Jr, Lemberg L, Arcebal AG. Mechanisms of slow ventricular tachycardias in acute myocardial infarction. Dis Chest. 1969;56(6):470-6. doi: 10.1378/chest.56.6.470
20. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115(15):2006-14. doi: 10.1161/CIRCULATIONAHA.106.653568
21. Abbas A, Matthews GH, Brown IW, et al. Cardiac MR assessment of microvascular obstruction. Br J Radiol. 2015;88(1047):20140470. 
doi: 10.1259/bjr.20140470
22. Bulluck H, Rosmini S, Abdel-Gadir A, et al. Diagnostic performance of T1and T2mapping to detect intra myocardial hemorrhage in reperfused ST segment elevation myocardial infarction (STEMI) patients. J Magn Reson Imaging. 2017;46:877-86. doi: 10.1002/jmri.25638

М.А. Тереничева*1, О.В. Стукалова1, Р.М. Шахнович1, С.К. Терновой1,2

1 Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия; 
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*starcad@bk.ru

________________________________________________

Mariya A. Terenicheva*1, Olga V. Stukalova1, Roman M. Shakhnovich1, Sergey K. Ternovoy1,2

1 Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Moscow, Russia; 
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*starcad@bk.ru